Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-06-18

HGF/SF and MET in metastasis

Objective

The growth and motility factor HGF/SF and its receptor MET define a paracrine signalling system which controls the migration of several cell lineages in embryogenesis and tissue repair. In a large number of human tumours, cancer cells hijack HGF/SF and MET signalling in order to invade adjacent tissue and initiate metastasis. The evidence for this is strong, broad and consistent and highlights HGF/SF and MET as key effectors of tumour invasion and primary targets for therapy. This proposal has two objectives. The first is to understand the mechanism by which HGF/SF and MET cause tumour invasion and, specifically: - how local hypoxia induces MET over-expression in tumour cells and how the MET - WNT and the MET - chemokine pathways cooperate in metastasis. The second aim is to develop MET therapeutics. These will include: (i) a protein antagonist built from a fragment of the ligand known as NK1, (ii) low molecular weight MET antagonists and, (iii) inhibitors of SHP-2, a critical effector of MET signalling. NK1 will be engineered as a receptor antagonist on the strength of available crystal structures. Low molecular weight MET antagonists and SHP-2 inhibitors will be developed on the strength of: - the availability of recombinant forms of the target proteins, - suitable screening methodologies and, - the results of initial screens that have provided robust proof of principle for both approaches. The proposal thus builds on strong progress in participating laboratories on the structure and function of HGF/SF and MET and fulfils the three key criteria described in the call for proposal ‘Understanding and fighting metastasis’, namely: (i) it addresses a key mechanism of dissemination of human tumours, (ii) contributes to understanding the interplay between the tumour microenvironment (the source of HGF/SF) and tumour cells (the cells that express the MET receptor) and, (iii) has considerable prospects of delivering novel therapeutics for metastatic cancer

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

FP7-HEALTH-2007-A
See other projects for this call

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

CP-FP - Small or medium-scale focused research project

Coordinator

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
EU contribution
€ 1 352 224,00
Address
TRINITY LANE THE OLD SCHOOLS
CB2 1TN Cambridge
United Kingdom

See on map

Region
East of England East Anglia Cambridgeshire CC
Activity type
Higher or Secondary Education Establishments
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Participants (3)

My booklet 0 0